Shall We Dance? Extending TANGO’s Results to Clinical Practice-Reference-Cited by-同舟云学术

Shall We Dance? Extending TANGO’s Results to Clinical Practice

Published:2020-03-21 Issue:7 Volume:71 Page:e200-e201
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Borghetti Alberto¹,Ciccullo Arturo²^ORCID,Baldin Gianmaria³^ORCID,Rusconi Stefano⁴,Capetti Amedeo⁵,Sterrantino Gaetana⁶,Gennari William⁷,Mussini Cristina⁸,Borghi Vanni⁸,Di Giambenedetto Simona¹²

Affiliation:

1. Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Unità Operativa Complessa Malattie Infettive, Rome, Italy

2. Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy

3. Mater Olbia Hospital, Olbia, Italy

4. Infectious Diseases Unit, Dipartimento di Scienze Biomediche e Cliniche Luigi Sacco, University of Milan, Milan, Italy

5. Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy

6. Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy

7. Laboratorio di Microbiologia e Virologia, Azienda Ospedaliero Universitaria di Modena, Modena, Italy

8. Clinica Malattie Infettive e Tropicali, Azienda Ospedaliero Universitaria di Modena, Modena, Italy

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa313/33216331/ciaa313.pdf

Reference5 articles.

1. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial;Taiwo;Clin Infect Dis,2018

2. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: Phase 3, randomized, non-inferiority TANGO study;van Wyk;Clin Infect Dis,2020

3. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients;Maggiolo;BMC Infect Dis,2017

4. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients;Hidalgo-Tenorio;Medicine (Baltimore),2019

5. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure;Borghetti;HIV Med,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study;Journal of Medical Virology;2023-10

2. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study;Journal of Global Antimicrobial Resistance;2022-03

3. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort;Viruses;2022-01-17

4. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding;JAIDS Journal of Acquired Immune Deficiency Syndromes;2021-11-01

5. Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens;International Journal of STD & AIDS;2021-06-22